SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Exclusion Criteria

• •1. Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks before the first dose of the study
• •2. HER2 posotive (IHC 3+ or IHC 2+/ISH +);
• •3. Toxicities caused by previous anticancer therapy were not recovered to CTCAE 5.0 Grade≤1;
• •4. Individuals with Leptomeningeal metastasis or Active brain metastases;
• •5. Individuals with a history of GI perforation or fistula, unstable GI bleeding;
• •6. Individuals with a history of severe cardiovascular and cerebrovascular diseases;
• •7. The researcher determined that there are other situations that are not suitable for participation.